SecBot SecBot
SECBOTREPLAY Home › Report › EVAX

EVAX · Evaxion announced two abstracts accepted for presentation at the AACR…

Evaxion · PRESS-RELEASE filed Mar 17, 2026 at 16:30 ET

At the news

NEUTRALIMPACT 4/10

PRESS-RELEASE filed Mar 17, 2026 at 16:30 ET

Evaxion announced two abstracts accepted for presentation at the AACR Annual Meeting, featuring new biomarker and immunogenicity data for its personalized cancer vaccine EVX-01 in melanoma, and preclinical data on using its AI-Immunology™ platform to target glioblastoma. The company will also participate in an industry partnering event, signaling efforts to advance collaborations.

  • Two abstracts accepted for AACR 2026 presentation: one on EVX-01 clinical data in advanced melanoma, another on AI-identified neoantigens for glioblastoma.
  • EVX-01 data includes durable de novo T-cell responses from a Phase 2 trial combining the vaccine with KEYTRUDA® (pembrolizumab).
  • Glioblastoma research is preclinical, focusing on endogenous retrovirus (ERV)-derived neoantigens identified via AI-Immunology™.
  • Evaxion will attend the AACR Oncology Industry Partnering event, indicating business development activity.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access